Steven Boyd, Director, 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 438,000 shares at $0.82 ($355K) on 2022-02-17, disclosed to the SEC on 2022-02-22.
Open-market purchase of $355k AVTX by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.82 | 150,000 | $123K | 34.6% |
| 2 | $0.82 | 150,000 | $123K | 34.6% |
| 3 | $0.82 | 55,000 | $45K | 12.7% |
| 4 | $0.77 | 83,000 | $64K | 18.0% |
| Total | $0.81 avg | 438,000 | $355K | 100% |
| Filing → |
| CERC | BUY | 2021-08-18 | $194K | — | Filing → |
| EYEG | SELL | 2021-07-29 | $27.9M | — | Filing → |
| RSLS | SELL | 2021-06-22 | $28.5M | — | Filing → |